cholestyramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	727	11041-12-6

Description:

Molecule	Description
Synonyms: colestyramine cholestyramine cholestyramine chloride colestyramin	Molecular weight: 1162 Formula: C68H97Cl5N5 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

colestyramine
cholestyramine
cholestyramine chloride
colestyramin

Molecular weight: 1162
Formula: C68H97Cl5N5
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
14	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Aug. 3, 1973	FDA	BRISTOL MYERS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	187.94	13.00	453	13448	714913	62760208
Product taste abnormal	92.13	13.00	29	13872	2038	63473083
Frequent bowel movements	91.29	13.00	59	13842	22963	63452158
Product physical consistency issue	77.62	13.00	20	13881	679	63474442
Product solubility abnormal	64.49	13.00	18	13883	832	63474289
Product residue present	56.47	13.00	24	13877	3955	63471166
Colitis	51.14	13.00	58	13843	48470	63426651
Laparotomy	43.29	13.00	11	13890	353	63474768
Abdominal pain	40.84	13.00	149	13752	293307	63181814
Intestinal anastomosis	40.66	13.00	11	13890	452	63474669
Bulimia nervosa	40.41	13.00	11	13890	463	63474658
Bowel movement irregularity	35.41	13.00	19	13882	5245	63469876
Toxicity to various agents	35.02	13.00	6	13895	247244	63227877
Faecal calprotectin increased	34.75	13.00	16	13885	3187	63471934
Contraindicated product administered	33.81	13.00	4	13897	217644	63257477
Gastrointestinal wall thickening	32.29	13.00	12	13889	1392	63473729
Cholangitis sclerosing	30.47	13.00	12	13889	1629	63473492
Clostridium difficile infection	30.23	13.00	35	13866	29887	63445234
Intestinal fibrosis	30.12	13.00	7	13894	153	63474968
Bile acid malabsorption	29.18	13.00	7	13894	176	63474945
Product use complaint	28.86	13.00	13	13888	2461	63472660
Glossodynia	28.51	13.00	3	13898	178873	63296248
Rheumatoid arthritis	28.50	13.00	10	13891	253809	63221312
Sacroiliitis	28.40	13.00	14	13887	3243	63471878
Intestinal resection	27.11	13.00	13	13888	2835	63472286
Ileal stenosis	26.54	13.00	11	13890	1702	63473419
Abdominal distension	25.86	13.00	58	13843	86557	63388564
Systemic lupus erythematosus	25.66	13.00	7	13894	208911	63266210
Cerebral venous sinus thrombosis	25.05	13.00	11	13890	1961	63473160
Ophthalmoplegia	24.73	13.00	10	13891	1454	63473667
Intestinal obstruction	24.51	13.00	32	13869	30867	63444254
Mesenteric vein thrombosis	23.75	13.00	9	13892	1101	63474020
Terminal ileitis	23.30	13.00	8	13893	738	63474383
Wound	23.02	13.00	4	13897	163259	63311862
Blood alkaline phosphatase increased	21.75	13.00	36	13865	42931	63432190
Small intestinal obstruction	21.17	13.00	23	13878	18314	63456807
Post procedural diarrhoea	21.06	13.00	7	13894	585	63474536
Therapeutic product effect decreased	21.02	13.00	8	13893	193179	63281942
Foreign body in throat	20.59	13.00	6	13895	324	63474797
Suprapubic pain	20.52	13.00	7	13894	633	63474488
Serum ferritin increased	20.07	13.00	14	13887	6168	63468953
Retching	19.83	13.00	20	13881	14625	63460496
Nephrolithiasis	19.69	13.00	34	13867	41950	63433171
Colectomy	19.21	13.00	10	13891	2596	63472525
Product odour abnormal	19.00	13.00	8	13893	1288	63473833
Flatulence	18.82	13.00	30	13871	34672	63440449
Pleural rub	18.45	13.00	4	13897	63	63475058
Intestinal stenosis	18.26	13.00	10	13891	2874	63472247
Crohn's disease	18.02	13.00	12	13889	4901	63470220
Proctalgia	17.90	13.00	13	13888	6097	63469024
Cystitis	17.74	13.00	38	13863	54953	63420168
Weight decreased	17.48	13.00	112	13789	276686	63198435
Intestinal anastomosis complication	17.40	13.00	5	13896	257	63474864
Sarcoma	16.99	13.00	6	13895	601	63474520
Drug level decreased	16.98	13.00	14	13887	7905	63467216
Cholecystitis infective	16.91	13.00	8	13893	1694	63473427
Remission not achieved	15.78	13.00	4	13897	127	63474994
Laboratory test abnormal	15.61	13.00	24	13877	26888	63448233
Alanine aminotransferase increased	15.50	13.00	54	13847	103716	63371405
Enterocutaneous fistula	15.22	13.00	7	13894	1390	63473731
Rash macular	15.22	13.00	22	13879	23342	63451779
Ileostomy	14.83	13.00	7	13894	1475	63473646
Gastrointestinal bacterial overgrowth	14.81	13.00	6	13895	876	63474245
Gastroenteritis	14.43	13.00	23	13878	26567	63448554
Muscle spasms	14.40	13.00	70	13831	156080	63319041
Aspartate aminotransferase increased	14.38	13.00	48	13853	90229	63384892
Red blood cell abnormality	14.33	13.00	5	13896	484	63474637
Short-bowel syndrome	14.14	13.00	5	13896	503	63474618
Jaundice	14.12	13.00	24	13877	29227	63445894
Klebsiella infection	14.05	13.00	13	13888	8553	63466568
Cholelithiasis	13.76	13.00	30	13871	43895	63431226
Ovarian cyst	13.41	13.00	17	13884	15928	63459193
Thyroidectomy	13.28	13.00	6	13895	1144	63473977
Drug intolerance	13.27	13.00	30	13871	308631	63166490
Benign vulval neoplasm	13.21	13.00	3	13898	59	63475062
General symptom	13.14	13.00	8	13893	2800	63472321

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	80.79	17.04	223	7268	389689	34559751
Alveolar lung disease	73.64	17.04	17	7474	369	34949071
Pulmonary interstitial emphysema syndrome	68.47	17.04	17	7474	507	34948933
Diffuse alveolar damage	47.17	17.04	18	7473	2296	34947144
Intestinal intraepithelial lymphocytes increased	40.63	17.04	9	7482	161	34949279
Intestinal obstruction	38.83	17.04	35	7456	22787	34926653
Nerve degeneration	38.82	17.04	9	7482	199	34949241
Cryptitis	37.69	17.04	9	7482	227	34949213
Eosinophilic pneumonia	36.82	17.04	17	7474	3484	34945956
Faecal calprotectin increased	35.28	17.04	15	7476	2529	34946911
Product taste abnormal	34.64	17.04	12	7479	1162	34948278
Microvillous inclusion disease	33.88	17.04	8	7483	192	34949248
Apoptosis	32.74	17.04	9	7482	402	34949038
Probiotic therapy	31.20	17.04	7	7484	133	34949307
Hemivertebra	30.31	17.04	7	7484	152	34949288
Abdominal rigidity	29.26	17.04	11	7480	1346	34948094
Hepatic enzyme abnormal	27.75	17.04	13	7478	2753	34946687
Hyperammonaemia	27.26	17.04	17	7474	6350	34943090
Transaminases abnormal	26.68	17.04	7	7484	261	34949179
Biopsy	25.61	17.04	7	7484	306	34949134
Bacterial diarrhoea	24.59	17.04	5	7486	58	34949382
Small intestinal obstruction	23.72	17.04	22	7469	14844	34934596
Colitis microscopic	23.49	17.04	11	7480	2326	34947114
Renal mass	22.92	17.04	10	7481	1794	34947646
Vascular device infection	22.67	17.04	13	7478	4172	34945268
Renal neoplasm	22.58	17.04	9	7482	1288	34948152
Dehydration	22.48	17.04	70	7421	129899	34819541
Oesophageal atresia	22.19	17.04	7	7484	506	34948934
Hepatic encephalopathy	22.03	17.04	21	7470	14664	34934776
Enterocolonic fistula	22.00	17.04	5	7486	101	34949339
Inappropriate schedule of product administration	21.89	17.04	44	7447	62252	34887188
Erosive duodenitis	20.11	17.04	9	7482	1715	34947725
Drug ineffective	19.89	17.04	166	7325	456585	34492855
Escherichia urinary tract infection	19.16	17.04	11	7480	3535	34945905
Bone density decreased	19.14	17.04	9	7482	1920	34947520
Generalised oedema	19.10	17.04	18	7473	12390	34937050
Arthralgia	18.69	17.04	79	7412	169962	34779478
Frequent bowel movements	18.64	17.04	18	7473	12769	34936671
Rectal haemorrhage	18.62	17.04	32	7459	40217	34909223
Glomerular filtration rate decreased	18.43	17.04	18	7473	12943	34936497
Eczema	18.05	17.04	21	7470	18415	34931025
Product solubility abnormal	18.04	17.04	6	7485	513	34948927
Abdominal adhesions	17.97	17.04	8	7483	1505	34947935
Poor venous access	17.68	17.04	12	7479	5171	34944269
Eye haemorrhage	17.19	17.04	11	7480	4294	34945146
Myalgia	17.10	17.04	48	7443	84062	34865378

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	131.21	13.34	432	15680	880057	78848219
Pulmonary interstitial emphysema syndrome	69.49	13.34	17	16095	506	79727770
Alveolar lung disease	67.83	13.34	17	16095	560	79727716
Faecal calprotectin increased	63.28	13.34	28	16084	5513	79722763
Frequent bowel movements	58.09	13.34	48	16064	29491	79698785
Product solubility abnormal	50.24	13.34	15	16097	957	79727319
Intestinal obstruction	49.77	13.34	52	16060	42968	79685308
Product physical consistency issue	46.92	13.34	14	16098	891	79727385
Abdominal pain	43.02	13.34	174	15938	389395	79338881
Intestinal resection	42.95	13.34	19	16093	3738	79724538
Toxicity to various agents	42.57	13.34	16	16096	421524	79306752
Small intestinal obstruction	40.92	13.34	38	16074	27234	79701042
Intestinal intraepithelial lymphocytes increased	40.64	13.34	9	16103	171	79728105
Diffuse alveolar damage	40.47	13.34	18	16094	3586	79724690
Vascular device infection	36.83	13.34	24	16088	10252	79718024
Nerve degeneration	36.34	13.34	9	16103	282	79727994
Bowel movement irregularity	36.27	13.34	20	16092	6314	79721962
Cryptitis	36.13	13.34	9	16103	289	79727987
Eosinophilic pneumonia	33.84	13.34	18	16094	5292	79722984
Microvillous inclusion disease	33.41	13.34	8	16104	217	79728059
Product residue present	31.39	13.34	15	16097	3521	79724755
Apoptosis	31.16	13.34	9	16103	511	79727765
Product taste abnormal	30.94	13.34	13	16099	2258	79726018
Probiotic therapy	30.68	13.34	7	16105	153	79728123
Intestinal anastomosis	28.71	13.34	9	16103	676	79727600
Laparotomy	28.22	13.34	8	16104	425	79727851
Completed suicide	27.11	13.34	8	16104	245759	79482517
Product use complaint	26.60	13.34	12	16100	2471	79725805
Cholangitis sclerosing	25.91	13.34	12	16100	2625	79725651
Clostridium difficile infection	25.53	13.34	37	16075	42648	79685628
Abdominal adhesions	25.31	13.34	13	16099	3560	79724716
Enterocolonic fistula	25.23	13.34	6	16106	158	79728118
Dehydration	25.11	13.34	108	16004	248079	79480197
Abdominal distension	24.52	13.34	66	16046	119584	79608692
Colitis	24.47	13.34	49	16063	73258	79655018
Hepatic encephalopathy	24.07	13.34	27	16085	24139	79704137
Off label use	23.53	13.34	283	15829	906932	78821344
Bile acid malabsorption	23.50	13.34	6	16106	213	79728063
Colectomy	23.10	13.34	12	16100	3362	79724914
Inappropriate schedule of product administration	22.80	13.34	69	16043	133559	79594717
Terminal ileitis	22.31	13.34	8	16104	909	79727367
Intestinal stenosis	21.90	13.34	12	16100	3742	79724534
Cerebrovascular accident	21.79	13.34	75	16037	155217	79573059
Blood pressure increased	21.39	13.34	92	16020	211268	79517008
Abdominal rigidity	21.19	13.34	11	16101	3077	79725199
Poor venous access	21.10	13.34	22	16090	18127	79710149
Mesenteric vein thrombosis	20.12	13.34	9	16103	1818	79726458
Biopsy	19.95	13.34	7	16105	747	79727529
Therapeutic reaction time decreased	19.90	13.34	11	16101	3490	79724786
Gastrointestinal wall thickening	19.79	13.34	10	16102	2647	79725629
Hyperammonaemia	19.69	13.34	17	16095	11076	79717200
Product odour abnormal	19.34	13.34	8	16104	1336	79726940
Renal neoplasm	19.30	13.34	9	16103	1999	79726277
Bacterial diarrhoea	19.23	13.34	5	16107	191	79728085
Transaminases abnormal	19.03	13.34	7	16105	855	79727421
Ophthalmoplegia	18.92	13.34	10	16102	2902	79725374
Foreign body in throat	18.86	13.34	6	16106	473	79727803
Erosive duodenitis	18.85	13.34	9	16103	2108	79726168
Pleural rub	18.59	13.34	4	16108	66	79728210
Anal fissure	18.32	13.34	14	16098	7689	79720587
Blood alkaline phosphatase increased	18.27	13.34	40	16072	63624	79664652
Nephrolithiasis	18.24	13.34	36	16076	53255	79675021
Rheumatoid arthritis	17.77	13.34	10	16102	208460	79519816
Renal mass	17.64	13.34	10	16102	3330	79724946
Enteritis	17.53	13.34	18	16094	14565	79713711
Myopathy	17.19	13.34	21	16091	20542	79707734
Hernia	16.89	13.34	19	16093	17040	79711236
Arthralgia	16.84	13.34	183	15929	571620	79156656
Rectal haemorrhage	16.55	13.34	43	16069	76257	79652019
Contraindicated product administered	15.84	13.34	6	16106	157532	79570744
Metastasis	15.26	13.34	12	16100	6868	79721408
Proctalgia	15.12	13.34	14	16098	9987	79718289
Drug interaction	15.08	13.34	39	16073	415144	79313132
Sarcoma	14.93	13.34	6	16106	930	79727346
Jaundice	14.72	13.34	33	16079	53316	79674960
Muscle spasms	14.66	13.34	72	16040	174658	79553618
Lymphocyte count increased	14.59	13.34	11	16101	5921	79722355
Myalgia	14.52	13.34	75	16037	185566	79542710
Ileostomy	14.37	13.34	7	16105	1713	79726563
Weight decreased	14.05	13.34	121	15991	355077	79373199
Gastric polyps	14.04	13.34	9	16103	3738	79724538
Colitis ulcerative	13.78	13.34	25	16087	34717	79693559
Heart rate decreased	13.61	13.34	38	16074	70278	79657998
Incorrect dose administered	13.47	13.34	40	16072	76590	79651686
Benign vulval neoplasm	13.45	13.34	3	16109	59	79728217
Serum ferritin increased	13.40	13.34	13	16099	9834	79718442
Drug ineffective for unapproved indication	13.37	13.34	31	16081	51207	79677069
Pruritus	13.36	13.34	130	15982	394518	79333758

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AC01	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Bile acid sequestrants
FDA MoA	N0000175365	Bile-acid Binding Activity
FDA EPC	N0000180292	Bile Acid Sequestrant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Hyperlipidemia	indication	55822004	DOID:1168
Biliary Obstruction with Pruritus	indication
Poisoning by digitalis glycoside	off-label use	12876009
Chronic diarrhea	off-label use	236071009
Classical phenylketonuria	contraindication	7573000
Constipation	contraindication	14760008	DOID:2089
Hypovolemia	contraindication	28560003
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hemorrhoids	contraindication	70153002	DOID:9746
Kidney disease	contraindication	90708001	DOID:557
Calculus in biliary tract	contraindication	266474003
Complete Biliary Obstruction	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018811	VUID
N0000147114	NUI
D02690	KEGG_DRUG
2447	RXNORM
4018811	VANDF
CHEMBL1201625	ChEMBL_ID
1005	INN_ID
DB01432	DRUGBANK_ID
4B33BGI082	UNII
4435	MMSL
6264	MMSL
d00193	MMSL
001216	NDDF
387408001	SNOMEDCT_US
72824008	SNOMEDCT_US
C0008402	UMLSCUI
137699107	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
cholestyramine light	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0939	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
cholestyramine light	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0939	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0940	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	19 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0940	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	19 sections
Prevalite	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0036	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0536	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	19 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0536	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0536	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	24658-266	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	24658-270	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	24658-271	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	Human Prescription Drug Label	1	27241-134	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	20 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-265	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-266	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-267	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	42806-269	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	42806-270	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	42806-271	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	49884-465	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	49884-465	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	49884-466	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	49884-466	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
QUESTRAN	HUMAN PRESCRIPTION DRUG LABEL	1	49884-936	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	23 sections
QUESTRAN	HUMAN PRESCRIPTION DRUG LABEL	1	49884-937	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	23 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3415	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3845	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	12 sections
Cholestyramine Light	HUMAN PRESCRIPTION DRUG LABEL	1	51224-009	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	23 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	51224-011	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4812	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	14 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5526	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	14 sections